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Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) predicts adverse
prognosis in patients with stable coronary artery disease (CAD). However, the interaction with conventional risk
factors remains uncertain. Our aim was to assess whether the extent of LGE is an independent predictor of adverse
cardiac outcome beyond conventional risk factors, including left ventricle ejection fraction (LVEF).
Methods: We enrolled 376 patients (88% males, 64 ± 11 years) with stable CAD, who underwent LGE assessment
and a detailed conventional evaluation (clinical and pharmacological history, risk factors, ECG, Echocardiography).
During a follow-up of 38 ± 21 months, 56 events occurred (32 deaths, 24 hospitalizations for heart failure).
Results: LGE and LVEF showed the strongest univariate associations with end-points (HR: 13.61 [95%C.I.: 7.32-
25.31] for LGE≥ 45% of LV mass; and 12.34 [6.80-22.38] for LVEF≤ 30%; p< 0.0001). Multivariate analysis
identified baseline LVEF, loop diuretic therapy, moderate-severe mitral regurgitation and pulmonary hypertension
as significant predictors among conventional risk factors. According to a step-wise approach, LGE showed strong
association with prognosis as well (5.25 [2.64-10.43]; p< 0.0001). LGE significantly improved the model
predictability (chi-square 239 vs 221, F-test p< 0.0001) with an additive effect on the prognostic power of LVEF,
which however retained its prognostic power (4.89 [2.50-09.56]; p< 0.0001). Patients with LGE≥ 45% and/or
LVEF≤ 30% had much worse prognosis compared to patients without risk factors (annual event rates of 43% vs
3%; p< 0.0001). Interestingly LGE was a significant predictor when all cause mortality was analyzed as the only
endpoint.
Conclusions: This study demonstrates that LGE assessed by CMR is a robust independent non-invasive marker of
prognosis in stable CAD patients. LGE can integrate the available metrics to substantially improve risk stratification.Background
Late gadolinium enhancement (LGE), assessed with cardio-
vascular magnetic resonance (CMR), has high sensitivity
and specificity to detect and quantify fibrotic tissue due to
myocardial infarction (MI) [1-3].
Previous studies suggested that LGE predicts adverse
prognosis in patients with stable coronary artery disease
(CAD) [4-9]. Since it also predicts unfavourable left* Correspondence: oronzo.catalano@fsm.it
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reproduction in any medium, provided the orventricle (LV) remodelling after acute MI [10], LGE might
be considered a metric of LV pump dysfunction alternative
to ejection fraction (EF) or end-systolic volume (ESV).
Pathophysiologic correlation between LGE and LVEF and
equivalence of informative content seem to be supported
by studies showing that LGE inclusion in multivariate
models often leads to substantial blunting of the well
known prognostic power of LVEF [5,6]. Interestingly,
however, this evidence has not been confirmed by other
studies in which both scar extent and LVEF seem to have
an independent prognostic value [9,11]. Moreover, LGE
retains a prognostic significance in the subset of patientsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been found in patients with stable CAD and unrecognized
MI, with LGE prognostic power being incremental or
alternative to LVEF at multivariate analysis [4,8]. Thus, the
prognostic significance of LGE seems to be complex and
not yet completely elucidated.
The aim of our study was to assess whether, in a large
well-characterized population of patients with known
or suspected stable CAD the extent of LGE is an inde-
pendent predictor of adverse outcome in the long-term
beyond conventional risk factors, in particular LVEF.
Methods
Study population and design
We performed a single centre observational prospective
study. Inclusion criteria: consecutive patients clinically
referred for CMR from January 2002 to December 2006,
either with definite diagnosis or with a history suggesting
stable CAD. Exclusion criteria: recent acute coronary
syndrome (within 6 weeks), previous hospitalization for
heart failure (NYHA class IV or need of infusive therapy)
and signs of myocarditis, infiltrative or hypertrophic
cardiomyopathy and pericardial disease. Patients under-
went detailed clinical and instrumental risk stratification
and were prospectively followed up. The study was
approved by the Fondazione Maugeri ethical committee
and informed consent was obtained from patients.
Conventional risk assessment
Before CMR execution patients’ clinical history was
collected, including anthropometric data, atherosclerotic
risk factors profile, any documented CAD history, coron-
ary angiography, NYHA class and pharmacological
records. An ECG was also recorded the same day of CMR.
ECGs were automatically analysed about heart rate, PR
interval, QTc interval and QRS duration (E-Scribe System,
Mortara Rangoni Europe), and interpreted by a single
blinded reader (O.C.) with regard to rhythm, signs of LV
hypertrophy, left and right bundle branch block, ST
depression, negative T waves and Q waves presence.
Patients underwent an echocardiographic examination
within few days from CMR with up-to-date equipments
(Sonos 5500, Hewlett Packard; Sequoia 512, Acuson; Vivid
7, General Electric). We evaluated dimensions, mass,
segmental/global contractility and diastolic function of LV,
mitral regurgitation, RV dimension and function, and
pulmonary artery pressure (evaluation criteria for ECG
and Echo are provided in additional file 1).
CMR and LGE assessment
CMR was performed with a 1.0-T scanner with a
20mTgradient (Magneton Harmony, Siemens, Erlangen,
Germany) and a phased-array cardiac coil. LGE was
assessed by inversion-recovery turboFLASH sequences(TE 2.6 msec, FA 8°, inversion time 260–360 msec,
matrix 96 × 256; FOV 400 mm), 7–8 min after
0.15–0.20 mmol/kg intravenous injection of gadolinium
(Magnevist; Schering, Berlin, Germany; Multihance,
Bracco, Milan, Italy). Multiple 8 mm thick short-axis
slices (usually 8–10) with appropriate interslice space
(usually 2 mm) were used for a full coverage of LV.
Transmural extent of LGE was scored by consensus of
two experienced readers (O.C., G.M.), using a five point
scale: 0 = no LGE, 1 = 1–25%, 2 = 26–50%, 3 = 51–75%
and 4 = 76–100% of wall thickness [12]. Standard
17-segments segmentation of LV was used and total LGE
burden in percent of total LV mass was calculated ([total
score*100]/[17*4]). Maximal transmural extent and
spatial extent, that is maximal LGE score and the
number of affected segments, were considered too.Follow-up
Follow up visits were performed at our Centre every
1–24 months, depending on the clinical severity. Trans-
telephonic follow-up was collected only for those
patients whose last visit date was antecedent 6 month
database closure (March 2009).
Primary outcome measure was a composite clinical
end-point of all-cause mortality and new onset heart
failure (HF) requiring hospitalization (NYHA class IV or
need of infusive therapy). If the patients were admitted
to a hospital other than our institution we retrieved the
hospital record to confirm diagnosis, clinical parameters
and outcome.
Myocardial revascularization procedures occurring after
CMR were registered as well, to evaluate any modulating
effect of myocardial revascularization on prognostic
value of LGE.Statistics
Categorical variables were expressed as counts and
percentage, continuous variables as mean ± standard
deviation. Two sided P< 0.05 was the significance level
for hypothesis testing and SPSS Statistics 18.0 was the
statistical package we used.
Differences at baseline between patients with and
without events were tested with Pearson Chi-Square or
Fisher's exact test in case of categorical variables and
Student's t-test or Mann–Whitney U-test in case of
continuous variables.
Univariate hazard ratios were calculated by Cox analysis
after converting continuous variables into dichotomous
variables; cut-offs were taken from the literature. Specific-
ally dichotomization of LVEF was made according to the
more conservative SCDHeft cut-off (30%). If established
cut-offs were lacking, we used the 75th and the 95th
percentiles of the entire study population. Proportional
Table 1 Baseline characteristics and differences between patients with and without events in the follow-up
All patients Event free (n = 320) With events (n = 56) P Value*
ANTHROPOMETRY
Age (y) 64 ± 11 63± 11 68 ± 10 0.003
Sex (m) 292 (78%) 248 (76%) 44 (79%) 0.859
Body mass index 26± 4 26 ± 4 26 ± 4 0.300
CAD RISK FACTORS
Familiar history of CAD 170 (45%) 143 (45%) 27 (48%) 0.625
Smoking habit 220 (59%) 179 (56%) 41 (73%) 0.015
Diabetes 77 (21%) 66 (21%) 11 (20%) 0.867
Hypertension 218 (58%) 185 (58%) 33 (59%) 0.876
Hypercholesterolemia 214 (57%) 181 (57%) 33 (59%) 0.742
# risk factors 2.4 ± 1.1 2.4 ± 1.1 2.6 ± 1.1 0.159
CLINIC HISTORY
Previous CAD diagnosis 332 (88%) 277 (87%) 55 (98%) 0.012
Previous myocardial infarction 246 (65%) 202 (63%) 44 (79%) 0.025
NYHA classification (III class) 22 (6%) 11 (3%) 11 (20%) <0.0001
Revascularization in the follow-up 79 (21%) 73 (23%) 6 (11%) 0.040
PHARMACOLOGICAL THERAPY
β-blockers 289 (77%) 448 (78%) 41 (73%) 0.483
Ca++−antagonist 76 (20%) 62 (19%) 14 (25%) 0.334
Nitrates 159 (42%) 136 (43%) 23 (41%) 0.842
Loop diuretics 135 (36%) 95 (30%) 40 (71%) <0.0001
Aldosterone antagonist 51 (14%) 30 (9%) 21 (38%) <0.0001
ACE-inhibitors/AT1-receptors antagonist 304 (81%) 257 (80%) 47 (84%) 0.526
ASA 319 (85%) 275 (86%) 44 (79%) 0.156
Statins 280 (75%) 240 (75%) 40 (71%) 0.572
Anticoagulant 33 (9%) 18 (6%) 15 (27%) <0.0001
ECG
Heart rate (bpm) 65 ± 13 64± 12 73 ± 14 <0.0001
Non sinusal rhythm 12 (3%) 7 (2%) 5 (9%) 0.021
QRS duration (msec) 105± 21 103 ± 19 112 ± 27 0.022
QTc interval (msec) 425± 34 421 ± 32 447 ± 37 <0.0001
LV hypertrophy 58 (15%) 50 (14%) 8 (16%) 0.942
LBB block 59 (16%) 44 (14%) 15 (27%) 0.013
RBB block 16 (12%) 12 (12%) 4 (14%) 0.612
ST segment depression 46 (8%) 38 (7%) 8 (13%) 0.176
Negative T waves 184 (49%) 151 (47%) 33 (59%) 0.105
Q waves 164 (44%) 135 (42%) 29 (52%) 0.181
ECHOCARDIOGRAPHY
LV EDV (ml/m2) 59 ± 22 57± 20 74 ± 30 <0.0001
LV ESV (ml/m2) 31 ± 20 28± 16 49 ± 28 <0.0001
LV EF (%) 51 ± 13 53± 12 39 ± 15 <0.0001
LV WMSI 1.4 ± 0.5 1.4 ± 0.4 1.9 ± 0.5 <0.0001
LV mass (g) 188± 59 186 ± 57 202 ± 70 <0.0001
LV diastolic function (≥ pseudo-normal) 44 (12%) 25 (8%) 19 (34%) <0.0001
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Table 1 Baseline characteristics and differences between patients with and without events in the follow-up (Continued)
Mitral regurgitation (≥ moderate) 56 (15%) 36 (11%) 20 (36%) <0.0001
Pulmonary hypertension 34 (9%) 19 (6%) 15 (27%) <0.0001
RVIT dilatation 17 (5%) 12 (4%) 5 (9%) 0.085
RV dysfunction 38 (10%) 28 (9%) 10 (18%) 0.037
LATE GADOLINIUM ENHANCEMENT
Total burden (% of LV mass) 13 ± 15 10± 12 28 ± 22 <0.0001
Spatial extent (% of LV surface) 22 ± 22 18± 19 42 ± 29 <0.0001
Max transmural extent (% of wall thickness) 55 ± 39 51± 39 73 ± 39 <0.0001
LV = left ventricle; LBB = left bundle branch; RBB = right bundle branch; MR=mitral regurgitation; RVIT = right ventricle inflow tract.
* Pearson Chi-Square or Fisher's exact test (where appropriate) for categorical data; Student's t-test or Mann–Whitney test (# risk factors, LV WMSI, late
enhancement data) for numeric data.
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the log estimated cumulative baseline hazard against time.
Conventional variables correlated with prognosis (p< 0.1)
at a first multivariate analysis (step-wise forward selection,
forceful introduction of LVEF), were used to build the final
model in which LGE was introduced at the last step to test
the hypothesis of its independent prognostic value on top
of a conventional risk stratification approach. F-test
for extra sum of square principle was applied to assess
goodness of fit of the final model with respect to the
conventional nested model. Annual event rate and death
rate for patients at risk were calculated.Results
Four-hundred-ten patients were referred to our unit for
CMR assessment during the period of interest. Twenty-
seven (7%) were excluded according to the exclusion
criteria and seven (2%) patients were lost at follow-up.
Thus, 376 patients entered the study, with a definite
diagnosis of CAD at the enrolment in 332 cases (88%)
and suspicion history in 44 (12%). Patients were
followed-up for 38 ± 21 months, during which there were
56 events (32 deaths, 24 new onset HF cases).
Main baseline characteristics are reported in Table 1.
Overall the study cohort was characterized by high
prevalence of male sex (88%). History of previous MI
was detected in two thirds of cases. Pharmacological
treatment was characterized by high rates of beta-
blockers, ACE-inhibitors, ASA and statins administration
(70-85%) with no significant differences among patients
with and without events.Predictors of events
Survival Cox univariate analyses showed that outcome
was associated with several variables. As known from
previous studies, the most powerful predictors of events
were age, previous history of CAD, 3-vessel disease at
coronary angiography, NYHA class, need for diuretic
and anticoagulant therapy, heart rate, non sinus rhythm,QRS complex duration, QTc interval, LV volumes, LVEF,
LV wall motion score index, LV diastolic function, mitral
regurgitation, pulmonary hypertension and right
ventricle function. A revascularization procedure after
the study enrolment was a protecting factor against the
outcome. All LGE indexes were also strongly associated
with prognosis with total burden, that is the amount of
LGE in percent of total LV mass, showing the most
powerful correlation. The 95th percentiles was the best
cut-off and that was considered for further analysis.
Univariate hazard ratios with 95% confidence intervals of
all considered variables are shown in Table 2.
The step-wise inclusion of variable reaching the prede-
fined univariate p value threshold (p< 0.1) into a multi-
variate Cox model in which LVEF was forcefully
included, significantly improved the model predictability
(chi-square 163 vs 157, F test: p= 0.033) with respect to
considering LVEF alone. However, only loop diuretic
therapy (HR: 3.20 [95%C.I.: 1.71 – 5.97]; p= 0.003),
pulmonary hypertension (2.44 [1.27 – 4.70]; p= 0.008)
and moderate-severe mitral regurgitation (2.02 [95% CI:
1.06 – 3.85]; p= 0.028) were independently associated
with an adverse prognosis after considering LVEF
(5.54 [2.85 – 10.78]; p< 0.0001).Prognostic role of late gadolinium enhancement
Significant conventional variables as from the multivariate
analysis were used to build the final model, that included
LGE and showed LGE to be significantly associated
with an adverse prognosis in terms of death or new onset
HF. LGE introduction significantly improved the model fit
(chi-square 238 vs 223, F-test p=0.0001) with respect to
conventional variables alone. Moreover, LGE was the
strongest prognostic indicator with a 5.3 fold increase
of event risk at follow-up . However, LVEF retained a
comparable prognostic power with a 4.9 fold increase of
event risk (HRs shown in Table 3). Similar results were
obtained analysing only patients with MI history at the
enrolment (n=246), with a definite diagnosis of CAD at the








Age (75 y) 1.70 0.92 – 3.17 0.093
Male sex 0.92 0.67 – 1.27 0.614
Body mass index >30 1.04 0.49 – 2.20 0.916
RISK FACTORS
Familiar history of CAD 1.16 0.68 – 1.96 0.588
Smoking habit 2.22 1.23 – 4.00 0.008
Diabetes 0.88 0.45 – 1.70 0.698
Hypertension 1.00 0.59 – 1.70 0.999
Hypercholesterolemia 1.13 0.66 – 1.92 0.664
# risk factors≥ 3 1.58 0.93 – 2.69 0.093
CLINIC
Previous CAD diagnosis 8.76 1.21 – 63.3 0.032
Previous myocardial
infarction
2.51 1.32 – 4.76 0.005
NYHA classification≥ 3 5.81 2.99 – 11.3 <0.0001
Revascularization in the
follow-up
0.36 0.15 – 0.85 0.019
THERAPY
β-blockers 1.00 0.55 – 1.81 0.997
Ca++−antagonist 1.15 0.63 – 2.12 0.644
Nitrates 0.92 0.54 – 1.56 0.753
Loop diuretics 5.26 2.94 – 9.40 <0.0001
Aldosterone antagonist 5.69 3.29 – 9.86 <0.0001
ACE-inhibitors/AT1-receptors
antagonist
1.45 0.71 – 2.96 0.310
ASA 0.69 0.36 – 1.30 0.251
Statins 0.94 0.53 – 1.68 0.837
Anticoagulant 6.38 3.49 – 11.7 <0.0001
ECG
Heart rate (≥75 bpm) 2.80 1.62 – 4.84 <0.001
Non sinusal rhythm 4.19 1.67 – 10.54 0.002
QRS duration 2.62 1.47 – 4.70 0.001
QTc interval 4.34 2.53 – 7.46 <0.0001
LV hypertrophy 1.00 0.47 – 2.11 0.995
LBB block 1.63 1.07 – 2.48 0.024
RBB block 1.30 0.62 – 2.76 0.489
ST segment depression 1.60 0.73 – 3.54 0.245
Negative T waves 1.76 1.03 – 3.00 0.039
Q waves 1.55 0.92 – 2.62 0.102
ECHOCARDIOGRAPHY
LV EDV (≥ 105 ml/m2) 4.66 2.34 – 9.29 <0.0001
LV ESV (≥ 75 ml/m2) 8.95 4.55 – 17.60 <0.0001
LV EF (≤ 30%) 12.34 6.80 – 22.38 <0.0001
Table 2 Unadjusted hazard ratios for death or new heart
failure (Continued)
LV WMSI (≥ 2.32) 10.94 5.53 – 21.62 <0.0001
LV mass (≥ 310 g) 4.89 2.05 – 11.70 <0.001
LV diastolic function (≥
pseudo-normal)†
7.03 4.00 – 12.38 <0.0001
Mitral regurgitation (≥
moderate){
4.67 2.68 – 8.13 <0.0001
Pulmonary hypertension 4.86 2.68 – 8.80 <0.0001
RVIT dilatation 1.45 0.92 – 2.30 0.112
RV dysfunction 5.17 2.48 – 10.80 <0.0001
CMR
LGE total burden≥ 45% } 13.61 7.32 – 25.31 <0.0001
LGE total burden≥ 20% # 6.62 3.86 – 11.38 <0.0001
LGE spatial Extent≥ 68% } 9.27 4.86 – 17.66 <0.0001
LGE spatial Extent ≥16% # 4.96 2.60 – 9.45 <0.0001
LGE transmurality 4.82 2.81 – 8.31 <0.0001
LV = left ventricle; LVEF = left ventricle ejection fraction; LBB = left bundle
branch; RBB = right bundle branch; MR=mitral regurgitation; RVIT = right
ventricle inflow tract; LGE = late gadolinium enhancement.
† based on trans-mitral diastolic flow and pulmonary vein flow evaluation.
{ based on effective regurgitate orifice area.
} cut-off equal to the 95% percentile of the entire population.
# cut-off equal to the 75% percentile of the entire population.
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HRs of these analyses are provided in additional file 2.
Accordingly, LVEF less than 30% and LGE total burden
more than 45% of total LV mass (95th percentile of the
study population) sharply stratified the population at
risk. The absence of both risk factors identified patients
at low risk (n = 340), with event-free survival of 95% at
1 year, 92% at 3 years and 86% at 5 years, and mean
annual event rate of 3%; conversely the presence of at
least 1 of these risk factors identified patients at very
high risk (n = 36) with event-free survival of 60% at 1 year,
31% at 3 years and 21% at 5 years, and a mean annual
rate of 43% (Log-Rank test: p< 0.0001). Ten out of 36
(28%) patients at high risk would not have been identified
without considering LGE, since their LVEF was greater
than 30%.
Finally we repeated the analysis using total mortality as
the only endpoint and we found similar results. In this
group LGE was associated with significantly increased
risk of mortality (HR 3.78 [95% CI: 1.46 – 9.75];
p= 0.006). All-cause mortality showed survival of 97% at
1 year, 95% at 3 years and 92% 5 years, and mean annual
death rate of 2% in the group without risk factors;
compared to survival of 82% at 1 year, 63% at 3 years
and 53% at 5 years, and mean annual death rate of
14% in the group with risk factors (p< 0.0001). These
findings are graphically shown by Kaplan-Meyer curves
in the Figure 1.
Table 3 Adjusted hazard ratios for death or new heart







(≥ 45% of LV mass)
5.25 2.64 – 10.43 <0.0001
LVEF (≤ 30%) 4.89 2.50 – 9.56 <0.0001
Pulmonary hypertension
(sPAP ≥ 35 mmHg)
2.89 1.56 – 5.36 <0.001
Loop diuretics therapy 2.92 1.54 – 5.55 0.001
LGE = late gadolinium enhancement; LVEF = left ventricle ejection fraction;
sPAP = systolic pulmonary artery pressure.
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In the last decade LGE CMR has paved the way to a new
era in the assessment of CAD [1]. Indeed, for the first timeFigure 1 Prognostic value of late gadolinium enhancement and left v
cumulative incidence of death plus heart failure (panel a) or death alone (pthis technique allowed to pursue a direct detection and
quantification of areas of irreversibly injured myocardium.
Thus LGE enabled in vivo morphopathologic assessment
complementary to that of myocardium functionally
impaired but still viable (hibernating myocardium),
postulated from previous studies [13]. Accordingly, LGE
had the potential to become the technique of choice to
study myocardial viability. Recent studies have confirmed
this hypothesis by showing that (a) the lesser transmural
extent of scar is, the more likely functional recovery of a
segment will be after revascularization and (b) the amount
of viable plus normal segments is the best predictor of
global functional recovery [12,14].
In survival studies the extent of LGE has emerged as the
strongest prognostic factor in stable CAD patients with
previous MI [5,6]. This correlation further refines theentricle ejection fraction. Kaplan-Meier survival analysis showing the
anel b).
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directly reflects the amount of irreversibly injured myocar-
dium. Accordingly, these studies seem to support the
hypothesis that LVEF is no more significant once LGE is
included in multivariate models. On the other hand, the
idea of the predictive value of LVEF to be enclosed and
overtaken by LGE assessment, is in conflict with a previ-
ous scintigraphy study in sudden death survivors and in a
recent CMR study in hypertensive patients [9,11]. In these
two studies, indeed, LVEF remained an independent
predictor of events after the inclusion of scar dimension in
a multivariate analysis. Thus the interaction between LGE
and LVEF in stable CAD populations seems to be modu-
lated by the selection of specific subsets of patients.
Conventional risk stratification
Our study was aimed at verifying these findings in a
large group of unselected patients with stable CAD. For
this reason we intentionally avoid to enrol a highly
homogeneous study cohort by defining relatively loose
entry criteria. In this setting, we attempted to test the
hypothesis whether LGE is an independent predictor of
adverse cardiac outcome in the context of a complex
cohort undergoing a complete standard evaluation. We
believe this study is representative of clinical referral of
many outpatient CAD cardiology clinics.
We studied a group of 376 consecutive patients with
stable CAD and optimized medical therapy, who were
followed-up for an average time of 3 years. The conven-
tional prognostic factor included in the study confirmed
their association with adverse prognosis, thus further
strengthening the evidence that our study group is repre-
sentative of a general population with stable CAD. To
remove redundant information a multivariate analysis
was performed, which confirmed the expected strong
prognostic power of LVEF and showed a significant con-
tribution by only few other conventional variables. The
latter did not include myocardial revascularization, even
if it seemed to have a protective effect as from univariate
analysis.
Added value of late gadolinium enhancement
On top of relevant conventional variables, we found that
LGE was significantly and strongly associated with prog-
nosis in a multivariate model (5.3 fold risk increase for
LGE >45%). Even more importantly, the present study
showed that LGE extent is complementary to LVEF in
stratifying the risk of patients with stable CAD. A large
scar, replacing more than 45% of total LV mass, well
integrates with the generally accepted criterion of LVEF
lower than 30% in identifying patients at high risk of
death or HF. Accordingly, patients with either LGE ≥ 45%
or LVEF ≤ 30%, have completely different prognosis if
compared with patients without any of these risk factors,showing annual event rates of 43% versus 3% and mor-
tality rates of 14% versus 2%, respectively. Notably, about
30% of patients at high risk would not have been identi-
fied without including LGE into the stratification
process.
The result of the present study seems to reinforce the
idea of LGE as a predictor of prognosis that adds to
LVEF. In comparison to the studies of Roes et al. and
Kelle et al., that came to opposite results, our study con-
sidered similar end-points but did not have scar presence
as an inclusion criterion (approximately 70% of our
patients were LGE positive). Accordingly, on average
scar dimension was smaller (13% vs 19–20% of total
mass) and EF higher (51 vs 43–44%). Thus, it may be
hypothesized that the pre-selection of patients with a
scar among those with stable CAD may influence the
interaction between LGE and LVEF in the prediction of
future events.
Understanding the relative relevance of LGE and LVEF
is not a purely theoretical issue. Indeed, in patients with
stable CAD reduced LVEF is a pre-requisite for important
therapeutic decisions, such as cardiac resynchronization
therapy (CRT) or automatic implantable cardioverter-
defibrillator (AICD). Thus, will LGE be confirmed a stron-
ger predictor than LVEF, the management of patients with
stable CAD could be substantially changed
Conclusions
Our study confirms and refines the evidence of LGE as
strong prognostic factor in unselected patients with stable
CAD, showing a complementary role with respect to LVEF.
Although further studies are warranted to assess the useful-
ness of LGE as selection criterion for major therapeutic
decision such as CRT or AICD, findings of the present
study promote the inclusion of LGE into current clinical
management of patients with stable CAD, especially of
those with reduced LVEF at echocardiography.
Additional files
Additional file 1: Table 1. Evaluation criteria of ECG and
Echocardiography. LV = left ventricle; LBB = left bundle branch; RBB = right
bundle branch; MR =mitral regurgitation; sPAH = systolic pulmonary artery
hypertension; RV = right ventricle; RVIT = right ventricle inflow tract;
TAPSE = tricuspid anular plane systolic excursion * based on trans-mitral
diastolic flow and pulmonary vein flow evaluation † based on proximal
isovelocity surface area radius.
Additional file 2: Table 2. Adjusted hazard ratios for death or new
heart failure of the final model for patients with myocardial infarction
history (panel a), with definite diagnosis of coronary artery disease (panel
b), and using MR derived left ventricle ejection fraction (panel c).
LGE = late gadolinium enhancement; LVEF = left ventricle ejection fraction;
sPAP = systolic pulmonary artery pressure.
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